Lopinavir-ritonavir for SARS-CoV-2 infection: a systematic review

1. Mohan BS, Nambiar V, et al., COVID-19: An Insight into SARS-CoV-2 Pandemic Originated at Wuhan City in Hubei Province of China. J Infect Dis Epidemiol, 2020 6:146. doi.org/10.23937/2474-3658/1510146 Mohan BS Nambiar V , COVID-19: An Insight into SARS-CoV-2 Pandemic Originated at Wuhan City in Hubei Province of China . J Infect Dis Epidemiol , 2020 6 : 146 . doi.org/ 10.23937/2474-3658/1510146 Open DOISearch in Google Scholar

2. Vargas M., Servillo G., Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. European Review for Medical and Pharmacological Sciences, 2020. 24:p. 1. Vargas M. Servillo G. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review . European Review for Medical and Pharmacological Sciences , 2020 . 24 :p. 1 . Search in Google Scholar

3. Cao, B., Wang, Y., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020, 382, 1787–1799., DOI : 10.1056/NEJMoa2001282 Cao B. Wang Y. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 . N. Engl. J. Med . 2020 , 382 , 1787 – 1799 ., DOI : 10.1056/NEJMoa2001282 Open DOISearch in Google Scholar

4. Wang, J. Fast identification of possible drug treatment of Coronavirus Disease-19 (COVID-19) through computational drug repurposing study. J. Chem. Inf. Model. 2020, 60, 3277–3286 Wang J. Fast identification of possible drug treatment of Coronavirus Disease-19 (COVID-19) through computational drug repurposing study . J. Chem. Inf. Model . 2020 , 60 , 3277 – 3286 Search in Google Scholar

5. Nutho, B., Mahalapbutr, P., Why are Lopinavir and Ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry 2020, 59, 1769–1779. Nutho B. Mahalapbutr P. Why are Lopinavir and Ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms . Biochemistry 2020 , 59 , 1769 – 1779 . Search in Google Scholar

6. Yan D, Liu XY, Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalized non-critically ill patients with SARS-CoV-2 infection. Eur Respir J. 2020 Jul 16;56(1):2000799. Yan D Liu XY Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalized non-critically ill patients with SARS-CoV-2 infection . Eur Respir J . 2020 Jul 16 ; 56 ( 1 ): 2000799 . Search in Google Scholar

7. Lecronier M, Beurton A, Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: An opportunistic retrospective analysis. Crit Care 2020;24:418. Lecronier M Beurton A Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: An opportunistic retrospective analysis . Crit Care 2020 ; 24 : 418 . Search in Google Scholar

8. Kim JW, Kim EJ, Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. Korean J Intern Med. 2020 Jun 16. Kim JW Kim EJ Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019 . Korean J Intern Med . 2020 Jun 16 . Search in Google Scholar

9. Lee JE, Lee SO, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study. Antiviral Therapy. 2021;26(1-2):34–42. doi:10.1177/13596535211039394 Lee JE Lee SO Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study . Antiviral Therapy . 2021 ; 26 ( 1-2 ): 34 – 42 . doi: 10.1177/13596535211039394 Open DOISearch in Google Scholar

10. Arabi YM, Gordon AC, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021;47(8):867–886. doi:10.1007/s00134-021-06448-5 Arabi YM Gordon AC Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial . Intensive Care Med . 2021 ; 47 ( 8 ): 867 – 886 . doi: 10.1007/s00134-021-06448-5 Open DOISearch in Google Scholar

11. Yueping Li, Zhiwei Xie, Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial, Clinical Advances, 2020, 1. Li Yueping Xie Zhiwei Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial , Clinical Advances , 2020 , 1 . Search in Google Scholar

12. Ye X.T., Luo Y.L, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur. Rev. Med. Pharm. Sci. 2020, 24, 3390–3396. Ye X.T. Luo Y.L Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 . Eur. Rev. Med. Pharm. Sci . 2020 , 24 , 3390 – 3396 . Search in Google Scholar

13. Kocayiğit H, Özmen Süner K, et al. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. J Clin Pharm Ther. 2021;46(2):454–459. doi:10.1111/jcpt.13305 Kocayiğit H Özmen Süner K Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19 . J Clin Pharm Ther . 2021 ; 46 ( 2 ): 454 – 459 . doi: 10.1111/jcpt.13305 Open DOISearch in Google Scholar

14. Lowe DM, Brown LK, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomized, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. PLoS Med. 2022;19(10): e1004120. Published 2022 Oct 19. DOI: 10.1371/journal.pmed.1004120 Lowe DM Brown LK Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomized, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 . PLoS Med . 2022 ; 19 ( 10 ): e1004120 . Published 2022 Oct 19. DOI: 10.1371/journal.pmed.1004120 Open DOISearch in Google Scholar